The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The firm also offers an NIPT, codeveloped with Yale, that its CEO said is differentiated by its rapid time-to-result.
It will use the funds to help expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection.
Researchers showed in a new study that patterns of methylation co-occuring at different sites could help distinguish cancer DNA in the blood, and mark its original source in body.
The company was founded in mid-2014 to commercialize noninvasive prenatal testing technologies developed at Johns Hopkins and UCSD.
The company's technology will be used to analyze samples from a large cohort of Chinese volunteers to identify biomarkers for early cancer detection.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.